Evidence mapPaperPMID 17599427Full record

Trial reportThe American journal of cardiology2007

Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Connie Kingry, Arnaud Bastien, Gillian Booth, Therese S Geraci, Brenda R Kirpach, Laura C Lovato, Karen L Margolis, Yves Rosenberg, JoAnne M Sperl-Hillen, Laura Vargo and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The American journal of cardiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000620. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000620 phase3completed

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Ran1999Enrolled10,251Registered outcomes6Posted comparisons6ConditionsAtherosclerosis, Cardiovascular Diseases, Coronary Disease, Diabetes MellitusArmsAnti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Open the trial in the graph
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Glucose targets for preventing diabetic kidney disease and its progression.The Cochrane database of systematic reviews · 2017
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Lifestyle interventions and independence for elders study: recruitment and baseline characteristics.The journals of gerontology. Series A, Biological sciences and medical sciences · 2013
    Trial
  10. Therapeutic hypothermia after pediatric cardiac arrest trials: the vanguard phase experience and implications for other trials.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2013
    Trial
  11. Effects of intensive glucose lowering in type 2 diabetes.The New England journal of medicine · 2008 · on this map
    Trial
  12. Article
  13. Representation of Women in Contemporary Kidney Transplant Trials.Transplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  14. Article
  15. Article
  16. Psychological and Biological Pathways Linking Perceived Neighborhood Characteristics and Body Mass Index.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2019
    Article
  17. Research site mentoring: A novel approach to improving study recruitment.Contemporary clinical trials communications · 2018
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Connie KingryDivision of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle, Washington 98103, USA. ckingry@u.washington.edu
Arnaud Bastien
Gillian Booth
Therese S Geraci
Brenda R Kirpach
Laura C Lovato
Karen L Margolis
Yves Rosenberg
JoAnne M Sperl-Hillen
Laura Vargo
Jeff D Williamson
Jeffrey L Probstfield
ACCORD Study Group

Funding

PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095183 · MINNEAPOLIS MEDICAL RESEARCH FDN, INC. · 1999 to 2000
$1.9M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095181 · CASE WESTERN RESERVE UNIVERSITY · 1999 to 2000
$1.8M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095184 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 1999 to 2000
$1.7M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095182 · WAKE FOREST UNIVERSITY · 1999 to 2000
$1.6M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS-N01HC95178N01HC095178 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 1999 to 2005
$1.5M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETER MELLLITN01HC095180 · UNIVERSITY OF WASHINGTON · 1999 to 2000
$1.5M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095179 · MCMASTER UNIVERSITY · 1999 to 2000
$1.3M
NHLBI NIH HHS N01-HC-95178NHLBI NIH HHS N01-HC-95179NHLBI NIH HHS N01-HC-95180NHLBI NIH HHS N01-HC-95181NHLBI NIH HHS N01-HC-95182NHLBI NIH HHS N01-HC-95183NHLBI NIH HHS N01-HC-95184NHLBI NIH HHS Y1-HC-1010NHLBI NIH HHS Y1-HC-9035
6 · The paper itself

Abstract

The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is a randomized, multicenter clinical trial using a double 2 x 2 factorial design in 10,251 participants with type 2 diabetes mellitus at high risk for cardiovascular disease (CVD) events. ACCORD is testing 3 complementary medical treatment strategies that may reduce high rates of major CVD morbidity and mortality in patients with type 2 diabetes. The ACCORD vanguard phase, conducted at 59 clinics in the United States and Canada, recruited 1,174 participants in 20 weeks from January through June 1, 2001, with a recruitment efficiency (R-factor) of 0.65. The recruitment strategies used in this vanguard phase were almost exclusively chart and database review within clinical practices and institutions. Recruitment for the main trial began in February 2003, involved 77 clinics, and resulted in an additional 9,077 participants by October 29, 2005 (total, 10,251). The R-factor during main trial recruitment was 0.96. Although new and refined recruitment strategies were formulated from the vanguard experience, the most powerful determinant of improved recruitment efficiency was the immediate start of enrollment by most clinics at the beginning of the main trial. Recruitment in the main trial required only a brief extension of 3 months and facilitated the nearly complete capture of the expected number of person-years of observation. Described herein are vanguard and main trial recruitment activities, including strategy implementation, screening procedures, randomization results, problems encountered, and lessons learned.

Indexed as

Diabetes Mellitus, Type 2CanadaCoronary Artery DiseaseDiabetic AngiopathiesHumansPatient SelectionUnited States

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.